Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
As of today, Vertex Pharmaceuticals(VRTX) shares are valued at $432.22. The company's market cap stands at 109.66B, with a P/E ratio of 30.46.
As of 2025-11-27, Vertex Pharmaceuticals(VRTX) stock has fluctuated between $428.07 and $433.32. The current price stands at $432.22, placing the stock +1.0% above today's low and -0.3% off the high.
The Vertex Pharmaceuticals(VRTX)'s current trading volume is 1.15M, compared to an average daily volume of 1.48M.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $519.68 at its peak.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $519.68 at its peak.
VRTX News
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth I...
Ever wondered if Vertex Pharmaceuticals is a hidden gem or if its current share price leaves little room for upside? Let's dive in together and see what the num...
Prediction: Vertex will be much larger by the end of the decade. A lot can change in five years. Take Vertex Pharmaceuticals (VRTX +0.57%), for example. In lat...
Analyst ratings
58%
of 36 ratingsMore VRTX News
Vertex Pharmaceuticals (VRTX) halted standalone development of its pain drug VX-993 after disappointing results in a mid-stage clinical trial. This update, alon...
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our Twi...
Vertex Pharmaceuticals recently presented updated interim data from its RUBY-3 trial at ASN Kidney Week 2025, highlighting promising results for povetacicept in...